What is the most commonly used anticoagulant therapy in the US?

What is the most commonly used anticoagulant therapy in the US?

• A. Rivaroxaban
• B. Warfarin
• C. Heparin
• D. Enoxaparin

Answer: (B)

Warfarin remains the most commonly used anticoagulant for long-term therapy in the United States because it is effective across a wide range of conditions (such as atrial fibrillation, venous thromboembolism, and mechanical heart valves), is inexpensive, and is taken orally with a well-established method for monitoring and dose adjustment using the INR. Its reversibility with vitamin K adds a safety advantage, and it works in patient populations where many newer agents aren’t suitable. Although direct oral anticoagulants are increasingly used due to their convenience and lack of routine monitoring, warfarin’s broad applicability, especially for mechanical valves and certain renal conditions, keeps it as the standard in overall use. Parenteral agents like heparin and enoxaparin are mainly for inpatient or bridging roles, not long‑term outpatient therapy, and rivaroxaban, while common, has not surpassed warfarin in total prevalence across the population.

Warfarin remains the most commonly used anticoagulant for long-term therapy in the United States because it is effective across a wide range of conditions (such as atrial fibrillation, venous thromboembolism, and mechanical heart valves), is inexpensive, and is taken orally with a well-established method for monitoring and dose adjustment using the INR. Its reversibility with vitamin K adds a safety advantage, and it works in patient populations where many newer agents aren’t suitable. Although direct oral anticoagulants are increasingly used due to their convenience and lack of routine monitoring, warfarin’s broad applicability, especially for mechanical valves and certain renal conditions, keeps it as the standard in overall use. Parenteral agents like heparin and enoxaparin are mainly for inpatient or bridging roles, not long‑term outpatient therapy, and rivaroxaban, while common, has not surpassed warfarin in total prevalence across the population.